Mode
Text Size
Log in / Sign up
N/A N=30 Randomized Single-blind Treatment

Environmental Design for Behavioral Regulation in People With Dementia

Alzheimer Disease

Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Apr 2023
Primary outcome: Primary: Success Rate of Adherence — 2; 6; 7 Participants — p=0.12

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Standard Environmental Design (Behavioral); Individual Environmental Design (Behavioral); Placebo (Behavioral)
Age
Adult, Older Adult · 21+ yrs
Sex
All
Sponsor
Elizabeth K Rhodus
Primary completion
Oct 2021

Outcome Measures

OutcomeResultp-value
PRIMARY
Success Rate of Adherence
2; 6; 7 0.12
SECONDARY
Change in Occupational Performance
4.6; 3.6; 4.4; 4.6; 6.1; 6.6
SECONDARY
Change in Behavior
13.3; 9.8; 10.3; 8.9; 10.8; 8.4

Summary

Individuals with dementia present with changes in behaviors throughout the continuum of cognitive decline. Environmental features may be influential in behavioral regulation. The purpose of this study is to assess the feasibility of environmental design protocols in older adults with dementia and their caregivers. Thirty subjects with moderate to severe Alzheimer's disease as primary dementia type, and their caregivers, will be randomly assigned to one of three arms: standard care; standard environmental design protocol; or personalized environmental design protocol.

Eligibility Criteria

Inclusion Criteria

  • Men or women aged 21-90, inclusive.
  • Living at home in the community with one primary caregiver.
  • Diagnosis of Alzheimer's disease as primary dementia type of moderate to severe stages
  • Stable medical condition for one month prior to screening visit
  • Stable medications for 4 weeks prior to screening visit
  • Caregiver report of challenges related to behaviors within 4 weeks of study enrollment
  • Caregiver willing to participant throughout duration of study

Exclusion Criteria

  • Unstable medical conditions for 3 months prior to screening
  • Wheelchair or bed bound.
  • Residence in skilled nursing facility or facility-based care.
  • Skin lesions or skin abnormalities throughout upper extremities.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04555616). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search